Tirzepatide Outperforms Dulaglutide on Multiple Metabolic Measures After Meals in Japanese Diabetes Patients | Research

The takeaway

In a head-to-head comparison, tirzepatide improved postmeal glucose, insulin, glucagon, triglycerides, and body fat more than dulaglutide in Japanese patients with type 2 diabetes.

5 metabolic improvements
Tirzepatide significantly outperformed dulaglutide on glucose, insulin, glucagon, C-peptide, and triglyceride responses after a standardized meal

What the researchers found

All three doses of tirzepatide (5, 10, and 15 mg) showed statistically significant improvements in postprandial glucose, insulin, glucagon, C-peptide, and triglyceride levels compared to dulaglutide 0.75 mg after a standardized meal test at Week 32. Tirzepatide 10 mg and 15 mg also significantly reduced body weight, and all doses significantly reduced body fat mass compared to dulaglutide at Week 52.

These pharmacodynamic differences demonstrate that the dual GIP/GLP-1 agonist tirzepatide has superior metabolic normalization compared to the GLP-1-only agonist dulaglutide across multiple postprandial parameters in Japanese patients with type 2 diabetes.

Why it matters

This substudy provides detailed mechanistic evidence for why tirzepatide outperforms single-target GLP-1 agonists. By measuring postprandial metabolic responses and body composition, it shows that adding GIP receptor agonism to GLP-1 activity produces broader metabolic improvement — not just better blood sugar control, but also better insulin dynamics, glucagon regulation, triglyceride handling, and fat loss. This data supports the biological rationale for dual-agonist peptide drugs.

The numbers in context

n=48 (9+11+9+19) · 52-week study · Tirzepatide 5/10/15 mg vs dulaglutide 0.75 mg · Mean age 58.6 · BMI 27.5 · Baseline HbA1c 8.22% · Significant improvements in glucose, insulin, glucagon, C-peptide, triglycerides

How the study worked

Substudy of SURPASS J-mono, a 52-week, multicenter, randomized, double-blind, active-controlled Phase 3 trial in Japan. 48 patients were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or dulaglutide 0.75 mg. Postprandial metabolic variables were measured via standardized meal tolerance test at Week 32 (AUC0-6h for glucose, insulin, glucagon, C-peptide, triglycerides). Body composition was measured by bioelectrical impedance analysis at Week 52.

Who was studied

Japanese adults with type 2 diabetes, mean age 58.6 years, mean BMI 27.5, mean HbA1c 8.22%, mean diabetes duration 6 years

What this study cannot tell us

Very small substudy (n=48, with only 9-19 per group), limiting statistical power and generalizability. Japanese patients may have different metabolic characteristics than other populations. The dulaglutide comparator dose (0.75 mg) is the lower approved dose in Japan — comparison against higher doses or other GLP-1 agonists might yield different results. This is a substudy of a larger trial, so it was not specifically powered for the pharmacodynamic endpoints.

How to read the evidence

This is a substudy of a Phase 3 randomized, double-blind, active-controlled trial — a high-quality study design. However, the very small substudy size (n=48) limits the statistical robustness of the findings.

When this study was published

Published in 2023 from the SURPASS J-mono trial, this is part of the landmark clinical program that led to tirzepatide's approval. The pharmacodynamic insights remain highly relevant to understanding how this peptide drug class works.

The bigger picture

The SURPASS clinical trial program established tirzepatide as superior to GLP-1 agonists for HbA1c and weight outcomes. This substudy goes deeper, showing the metabolic mechanisms behind that superiority. Understanding that dual GIP/GLP-1 agonism improves multiple metabolic pathways simultaneously — including triglyceride handling and glucagon regulation — supports the development of next-generation multi-agonist peptides and helps clinicians understand the added value of dual-target therapy.

Questions still open

Would the pharmacodynamic advantages of tirzepatide over dulaglutide be maintained at higher dulaglutide doses?
Do these postprandial metabolic improvements translate to better long-term cardiovascular outcomes?
Are the metabolic response differences seen in Japanese patients generalizable to other ethnic populations?

Common questions

What is the difference between tirzepatide and dulaglutide?

Both are injectable peptide drugs for type 2 diabetes, but they work differently. Dulaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors. This dual action appears to produce broader metabolic benefits — better postmeal blood sugar control, improved insulin and glucagon regulation, lower triglycerides, and more body fat loss.

Why study postmeal metabolic responses?

After eating, blood sugar spikes and the body releases insulin, glucagon, and other hormones to manage the incoming nutrients. In diabetes, these postmeal responses are abnormal. Measuring them in detail — as this study did with a standardized meal test — reveals exactly how well a drug normalizes the body's metabolic response to food, providing deeper insight than just measuring fasting blood sugar or HbA1c.

Read the original research

Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).

Diabetes, obesity & metabolism, 25(2), 398-406

View on PubMed ↗Publisher’s paper ↗

Citation

Yabe, Daisuke; Kawamori, Dan; Seino, Yusuke; Oura, Tomonori; Takeuchi, Masakazu. (2023). Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).. Diabetes, obesity & metabolism, 25(2), 398-406. https://doi.org/10.1111/dom.14882